Compare WLKP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLKP | AKBA |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 756.4M | 729.1M |
| IPO Year | 2014 | 2014 |
| Metric | WLKP | AKBA |
|---|---|---|
| Price | $21.85 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 46.7K | ★ 3.0M |
| Earning Date | 02-23-2026 | 03-12-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $1,133,706,000.00 | $225,071,000.00 |
| Revenue This Year | $3.88 | $52.38 |
| Revenue Next Year | $12.71 | $22.45 |
| P/E Ratio | $15.72 | ★ N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $17.75 | $1.30 |
| 52 Week High | $25.04 | $4.08 |
| Indicator | WLKP | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 71.84 | 44.26 |
| Support Level | $21.03 | $1.37 |
| Resistance Level | $21.69 | $1.53 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 75.54 | 47.83 |
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.